All Team Company Patients Physicians Hospital Partners Mission Innovation Details Supporters Comments Updates



About our project The problem we solve: Over 400 Million people in the world, those with Diabetes, have to inflict pain on themselves multiple times every day in order to live a healthy life. In addition to the pain, they are required to endure addition expense by having to continuously purchase strips and lances, adding insult to injury. Shouldn't there be a better way? About our solution: Theory: The reaction of the pupil is a leading indicator of diabetic glucose levels Our solution employes two techniques: First: Placing the pupil in a light isolation environment, bathing the pupil with infrared light, and recording the pupillary reaction when we apply a short burst of stimulus (a white light). Second: Analyzing the video of the pupil reaction and compare the reaction of the pupil to previously derived, individualized baselines. The patient simply holds the GlucoSight to their eye for 8 seconds, we record the video, analyze the results and give them an indication as to whether their glucose level is healthy or not. There is a lot of lighting magic and proprietary software that we had to develop, but the pupillary reaction curve allows us to derive the patients glucose range. Progress to date: At this point we are pre-market. The IP has been filed, data collection is ongoing, hardware and software are on continuous innovation/quality cycles, and paths to market both domestically and internationally, direct and partnerships are being actively pursued. We are filing the initial paperwork for the FDA and will be launching a study with the Department of Endocrinology at a reputable Boston-based hospital and medical school in August and should have results very quickly as the GlucoSight feeds the resulting data into our cloud servers, allowing us immediate access to the data.

About Our Team Creator: Ken Steinberg Location: New Hampshire Bio: A 30-year industry veteran with a reputation as a prolific problem solver with a continuously growing portfolio of solutions (products, services, patents) in numerous fields including computer science, healthcare and consumer safety. Title: CEO/Founder Advanced Degree(s): BSCS About Team Members Jason Clark

Founder/ VP HW Engineering, BSEE

Biography: 20 Year industry veteran with an extensive background in mechanican, electrical, and software engineering. Jason has deveoped numerous products ranging from medical devices to lighting to robotics.

Title: Founder/ VP HW Engineering

Advanced Degree(s): BSEE

LinkedIn: https://www.linkedin.com/in/jasonclarknh

James Wilkie

Head of Regulatory Affairs, BS Plastics

Biography: A medical industry executive with extensive experience in M&A, R&D, regulatory affairs and operations in biotech, catheter and surgical product companies.

Title: Head of Regulatory Affairs

Advanced Degree(s): BS Plastics

LinkedIn: https://www.linkedin.com/in/jim-wilkie-b974861

Dave Hall

Dir, Business Development, BSME

Biography: Dave Hall has over 30 years experience in Sales, Marketing and Business Development, working as a Sales and Business Consultant for Electronics, Medical Device, Bio-Medical, IT and Industrial accounts. A Mechanical Engineering graduate from the University of New Hampshire

Title: Dir, Business Development

Advanced Degree(s): BSME

LinkedIn: https://www.linkedin.com/in/hallzy

John Brooks III

Advisor, MSBA

Biography: An industry stalwart with over two decades of work in diabetes including executive leadership at Joslin Diabetes Center, Pfizer, and Insulet.

Title: Advisor

Advanced Degree(s): MSBA

LinkedIn: https://www.linkedin.com/in/john-brooks-ab04432

Dan Grunberg

Advisor, PhD EECS - MIT

Biography: Founder of and Chief Science Officer for Immedia Semiconductor and President of Chainwave Systems, Dan is well-know for his expertise in imaging. Currently a principal at Apollo Partners specializing in health insurance services

Title: Advisor

Advanced Degree(s): PhD EECS - MIT

Dr Demetrios Vavvas

Advisor, M.D. Ph.D, Mass Eye and Ear

Biography: Demetrios Vavvas, M.D., Ph.D., is a full-time clinician scientist in the Retina Service of Mass. Eye and Ear, an Associate Professor of Ophthalmology with Harvard Medical School, a Principal Investigator in the Angiogenesis Laboratory, and the incumbent of the Monte J. Wallace Ophthalmology Chair in Retina.

Title: Advisor

Advanced Degree(s): M.D. Ph.D, Mass Eye and Ear

LinkedIn: http://www.masseyeandear.org/find-a-physician/v/vavvas-demetrios



About Our Company GlucoSight Location: 356 Main Dunstable Rd

Nashua, NH 03062 Founded: 2016 Website: http://www.glucosight.com Twitter: GlucoSight Facebook: https://www.facebook.com/GlucoSight Product Stage: Prototype/MVP YTD Sales: Working on it Employees: 5-10

How We Help Patients Early detection and ongoing maintenance are crucial to the longevity and health of someone with diabetes. Many of the complications arise when the patient does not properly monitor their blood sugar as prescribed. Unfortunately the cost and pain associated with traditional lance-based methods act as a detractor, a deterrent to the patients daily routine monitoring requirements. With a GlucoSight, we remove the negative (pain and cost) stimuli associated with monitoring one's blood sugar. We have had countless individuals ask us how to get a GlucoSight. They want relief, we all want to better outcomes, and a pain-free lifestyle.

How We Help Physicians Do you wish your patients managed their diabetes more consistently and reliably? Do you wish you could remotely monitor their efforts AND experience the effects on the physiology? Are you concerned for your patient’s overall health due to their poor monitoring habits? At GlucoSight, our intent is to drive better outcomes by making the process of monitoring blood glucose levels pain-free. Imagine the ability of a patient to simply look into a small, mobile-phone attached device and in matter of seconds know if they are hyper- or hypoglycemic. At the same time, these results, and physiological information, including actual video of their eyes, is readily available to you via your laptop or phone? All of this is potentially possible with your donation. Help us make better diabetic outcomes a reality! " placeholder="" maxlength="2000"> Do you wish your patients managed their diabetes more consistently and reliably? Do you wish you could remotely monitor their efforts AND experience the effects on the physiology? Are you concerned for your patient’s overall health due to their poor monitoring habits? At GlucoSight, our intent is to drive better outcomes by making the process of monitoring blood glucose levels pain-free. Imagine the ability of a patient to simply look into a small, mobile-phone attached device and in matter of seconds know if they are hyper- or hypoglycemic. At the same time, these results, and physiological information, including actual video of their eyes, is readily available to you via your laptop or phone? All of this is potentially possible with your donation. Help us make better diabetic outcomes a reality! " placeholder="" maxlength="2000"> Do you wish your patients managed their diabetes more consistently and reliably? Do you wish you could remotely monitor their efforts AND experience the effects on the physiology? Are you concerned for your patient’s overall health due to their poor monitoring habits? At GlucoSight, our intent is to drive better outcomes by making the process of monitoring blood glucose levels pain-free. Imagine the ability of a patient to simply look into a small, mobile-phone attached device and in matter of seconds know if they are hyper- or hypoglycemic. At the same time, these results, and physiological information, including actual video of their eyes, is readily available to you via your laptop or phone? All of this is potentially possible with your donation. Help us make better diabetic outcomes a reality!

How We Help Hospitals We know every member of your team cares about the health of your patients, but we also know it is a daily challenge to keep the cost of healthcare in check. We are here to help. With Medicare reimbursement cuts on the horizon, we can help reduce the cost of monitoring glucose levels and achieve better outcomes for your diabetic patients by eliminating the costs of lances, strips, excessive lab tests, and additional services due to poor glucose monitoring. With an 8 second video, we can help your staff work with your patients to easily and effectively monitor their diabetes. The time, cost, and long term complications that your hospital deals with every day might become a thing of the past. Donate and help us, help you!

How We Help Partners Imagine how GlucoSight effects all three of these areas; we can screen earlier and faster with less education; we can remove the costs of lances, strips, nursing time; we can increase outcomes due to easier monitoring. All with a simple mobile-device, a cellphone, and software, but with none of the headaches that go with producing, packing, and shipping sterile medical devices. Add to this cloud-based access to patient data and data analytics. Every data element and image collected by GlucoSight securely resides in the cloud where healthcare professionals can provide ongoing treatment adjustments. Not only does the patient benefit but so does their physician and fellow researchers. The market is changing. Companies, like GlucoSight, are racing for better, less costly, less painful, monitoring tools while others are striving for better treatment with innovations like the artificial pancreas. With tens of billions of dollars on the line, companies must either innovate or watch others cut into their bottom line. GlucoSight is poised to be a technology that will allow existing (or potential) market players to stay in the game by offering less expensive solutions to their customers, and better data to their researchers. Imagine how GlucoSight effects all three of these areas; we can screen earlier and faster with less education; we can remove the costs of lances, strips, nursing time; we can increase outcomes due to easier monitoring. All with a simple mobile-device, a cellphone, and software, but with none of the headaches that go with producing, packing, and shipping sterile medical devices. Add to this cloud-based access to patient data and data analytics. Every data element and image collected by GlucoSight securely resides in the cloud where healthcare professionals can provide ongoing treatment adjustments. Not only does the patient benefit but so does their physician and fellow researchers. The market is changing. Companies, like GlucoSight, are racing for better, less costly, less painful, monitoring tools while others are striving for better treatment with innovations like the artificial pancreas. With tens of billions of dollars on the line, companies must either innovate or watch others cut into their bottom line. GlucoSight is poised to be a technology that will allow existing (or potential) market players to stay in the game by offering less expensive solutions to their customers, and better data to their researchers. " rows="4" placeholder="" maxlength="2000"> Imagine how GlucoSight effects all three of these areas; we can screen earlier and faster with less education; we can remove the costs of lances, strips, nursing time; we can increase outcomes due to easier monitoring. All with a simple mobile-device, a cellphone, and software, but with none of the headaches that go with producing, packing, and shipping sterile medical devices. Add to this cloud-based access to patient data and data analytics. Every data element and image collected by GlucoSight securely resides in the cloud where healthcare professionals can provide ongoing treatment adjustments. Not only does the patient benefit but so does their physician and fellow researchers. The market is changing. Companies, like GlucoSight, are racing for better, less costly, less painful, monitoring tools while others are striving for better treatment with innovations like the artificial pancreas. With tens of billions of dollars on the line, companies must either innovate or watch others cut into their bottom line. GlucoSight is poised to be a technology that will allow existing (or potential) market players to stay in the game by offering less expensive solutions to their customers, and better data to their researchers.

Challenge Mission Market Size Focusing on the US market initially, we have had in-depth conversations with some of the distribution arms for the largest existing diabetes glucose meter "Big Box Retail/OEM" distributors in order to understand the scale and opportunity of the market. Based on their numbers, the US market consists of 20M glucose meters. Every year 20% of that market refreshes, meaning diabetics get new meters due to meter failures, new technology etc. This is approximately 4M meters a year. In order to determine a what percentage of these 4M units we could potentially capture annually, we ran a Facebook add for 45 days (see image) asking the Diabetic community if they would rather "Lance or Glance". In 45 days we got 84K impressions with a CTR (click thru rate) of 3.7%. Applying this rate to the 4M available units would equate to a reachable market of 150K units annually. Projected 3 Year Growth We have performed a 5 year detailed, P&L projection based on the Diabetes as a Service model which provides us with reocurring revenue of $60 per person per year. With a capture rate of 150K unit per year ($9M in annual revenue per 150K) we conservatively project US only revenue to be $27M by 2020 with an EBITDA of $12M. How We Will Make Money Given that our solution does not require the use of strips or lances this allows us the flexibilty to provide our solution at market disrupting prices. We are going to offer our solution as a service, Diabetes As A Service (DaaS). The consumer will sign up for the service for an initial fee of $9.99 and then pay $4.99 per month ($60 per year), unlimited usage. In additional we will charge care givers and physicians access to our cloud ports at a discounted monthly rate and will generate additional revenue via advertizements on our mobile application. We have also engaged one of the leading OEM/Big Box Retail distribution firms which will be handling the OEM and Retail strategy. This firm has over 10 years of experience selling into the existing retailers for firms such as DexCom, J&J, GE and others. They have all of the relationships necessary to bring an OEM product to market in under a year. About our Competition There are no companies that currently offer our technology or solution. There are a number of academic institutions which are working on products that analyze the chemical properties of tears and exhaled gases. These solutions require either implated devices or chemical analysis strips. We are the only company which is performing image analysis to determine Glucose range.